Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of Barclays kept BioMarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc (BMRN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 10,800,059 | $763,456,171 | +3% | 2.43% |
| 2. | Elliott Management Paul Singer | 3,500,338 | $247,438,893 | 1.63% | |
| 3. | AQR Capital Management Cliff Asness | 2,925,805 | $203,987,099 | +128% | 0.21% |
| 4. | Citadel Investment Group Ken Griffin | 1,595,058 | $112,754,650 | +312% | 0.02% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 1,388,728 | $98,169,182 | +101% | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.75 | 3,625 | $314,468.75 | 10,905 | 2022-10-31 | Filing | |
| $78.84 | 900 | $70,955.37 | 30,740 | 2020-08-31 | Filing | |
| $78.22 | 11,900 | $930,759.69 | 29,840 | 2020-08-31 | Filing | |
| $21.76 | 161 | $3,503.36 | 100,574 | 2012-10-31 | Filing | |
| $21.76 | 548 | $11,924.48 | 15,294 | 2012-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $59.31 | 1,786 | $105,927.66 | 14,173 | 2025-05-20 | Filing | |
| $64.92 | 273 | $17,723.16 | 32,700 | 2025-05-02 | Filing | |
| $71.52 | 1,295 | $92,618.40 | 16,955 | 2025-03-19 | Filing | |
| $71.28 | 7,034 | $501,355.38 | 87,655 | 2025-03-06 | Filing | |
| $68.38 | 1,344 | $91,902.72 | 13,105 | 2025-02-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 23,778,999 | $1,680,937,387 | 0.04% | |
| 2. | 19,003,212 | $1,343,337,056 | 0.02% | |
| 3. | 17,773,281 | $1,256,393,234 | 1.04% | |
| 4. | 14,955,240 | $1,057,185,916 | 0.6% | |
| 5. | 9,150,655 | $646,859,812 | 0.14% |
News See All
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Jim Cramer on BioMarin: “I Don't Think It Works Now”
BioMarin (NASDAQ:BMRN) is a biotechnology company focused on turning genetic research into treatments that significantly improve patients’ lives, supported by a history of innovation and a growing pipeline...
Jim Cramer Discussed These 16 Stocks Recently
“It's all coming together for the most speculative stocks in the market, and it's a dream come true for many dreamers… It's the year of magical thinking… and boy is that year ever paying off.
BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition
On May 16, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced a $270 million acquisition of Inozyme Pharma, aiming to expand its rare disease research.
15 Small-Cap Healthcare Stocks Hedge Funds Are Buying
The U.S. healthcare sector has performed better in 2025 compared to the broader market. After two years of weak performance, the healthcare sector kicked off on a strong note in 2025.
Billionaire Paul Singer's 10 Stock Picks with Huge Upside Potential
Paul Singer founded Elliott Investment Management in 1977 in New York. It is one of the oldest hedge funds under continuous management and is also one of the largest activist funds in the world.
10 Stocks That Will Make You Rich In 3 Years
The stock market has been facing volatility since the tariffs were announced. This has created fears of a recession, leading many investors to think that this might be the end of the bull market.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the BioMarin Pharmaceuticals First Quarter 2025 Conference Call. Just a reminder that this conference is being recorded.
Billionaire Andreas Halvorsen's 10 Stock Picks With Huge Upside Potential
Ole Andreas Halvorsen is one of the prominent names among former employees of Julian Robertson's Tiger Management.